Pharmaceutical Technology Editors

Facility will use mammalian cell-culture technology and be ready for operations by 2016.

Agreement seeks to advance novel drug targets and focus on therapies for ulcerative colitis.

Acquisition will strengthen AstraZeneca's respiratory portfolio with a potential new treatment for chronic obstructive pulmonary disease.

FDA Discovers Microbial Contamination in Compound Pharmacy Products

Modular containment room at Belfast facility allows studies of biologics and vaccines.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

The agreement is worth up to $552 million, depending on meeting set milestones.

Pfizer had gained the facility through its previous acquisition of King Pharmaceuticals.

-

Unither Pharmaceuticals will acquire an UCB Rochester, NY pharmaceutical plant used to liquid pharmaceutical products.

A new panel will create reports that assess changes in the pharmaceutical industry.

The companies cancel plans to develop and manufacture generic drugs in Japan.

With downsizing occurring more frequently than ever within the pharmaceutical industry, is Europe doing enough to curb further job losses that could threaten the recovery of its economy?

GSK expands its vaccines platform technology expertise by acquiring Okairos, a Swiss-based company.

Competence in process safety is important for preventing accidents.

FDA addresses shortages of drugs needed to treat premature infants and patients unable to eat or drink by mouth.

Cloud-computing solutions and software enable researchers to garner insight from large, public-health datasets.

ISTA will pay $33.5 million to resolve criminal liability and false claims allegations.

Johnson & Johnson anticipates submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017; the announcement was made at a recent meeting with industry analysts. Upcoming new products include simeprevir for hepatitis C (already filed in Japan, Europe and the US); ibrutinib and daratumumab for haematologic malignancies; sirukumab and guselkumab for diseases of the immune system such as rheumatoid arthritis and psoriasis; and vaccines for influenza, rabies and polio.

The South Wales, UK contained-manufacturing operation was built in less than a year using design-to-manufacture and modular approaches.

USP defers implementation date to work closely with ICH Q3D. USP will also form a new advisory group for implementation of the new general chapters on elemental impurities.

Valeant Pharmaceuticals and Bausch + Lomb have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash.

New design meets new process requirements.

Partnership will support development of drugs to fight antibiotic resistance and bioterrorism.

The U.S. Pharmacopeial Convention is offering free online access to public standards to help ensure the quality of the herbal ingredients used in medicinal products.

Actavis Inc. and Warner Chilcott plc have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion.

Program aims to develop a novel oral treatment.

Elan will purchase interest in four respiratory programs.

Thomson Reuters released a report that provides a view of the challenges facing companies entering the United States biosimilar drug market.

FDA has released guidance on best practices for conducting and reporting pharmacoepidemiologic safety studies.